Legal & General Group Plc Invests $8.80 Million in Avantor, Inc. $AVTR

Legal & General Group Plc purchased a new stake in shares of Avantor, Inc. (NYSE:AVTR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 888,490 shares of the company’s stock, valued at approximately $8,796,000. Legal & General Group Plc owned 0.13% of Avantor as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in Avantor by 119.1% in the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after purchasing an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC acquired a new position in Avantor during the 2nd quarter valued at about $32,000. Los Angeles Capital Management LLC bought a new stake in shares of Avantor during the 4th quarter worth about $32,000. Osaic Holdings Inc. raised its position in shares of Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after buying an additional 1,064 shares in the last quarter. Finally, SJS Investment Consulting Inc. lifted its stake in shares of Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock worth $41,000 after acquiring an additional 4,927 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AVTR has been the subject of several recent analyst reports. Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $13.00 target price on shares of Avantor in a research report on Thursday, July 30th. Wells Fargo & Company increased their price target on Avantor from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Citigroup lifted their price target on Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, TD Cowen reissued a “hold” rating on shares of Avantor in a research note on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

Avantor Stock Down 2.1%

Shares of Avantor stock opened at $14.23 on Wednesday. Avantor, Inc. has a 12-month low of $7.26 and a 12-month high of $15.93. The firm has a market capitalization of $9.62 billion, a PE ratio of -16.94, a price-to-earnings-growth ratio of 10.97 and a beta of 0.89. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The stock’s fifty day moving average is $12.32 and its 200-day moving average is $9.82.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.Avantor’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the company posted $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities analysts anticipate that Avantor, Inc. will post 0.81 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.